DOCSLIB.ORG

NORM/NORM-VET 2017 Should Include Specific Reference to This Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NORM/NORM-VET 2017 Should Include Specific Reference to This Report 2O17 NORM NORM-VET Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway 2017 NORM NORM-VET Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway ISSN: 1502-2307 (print) / 1890-9965 (electronic) Any use of data from NORM/NORM-VET 2017 should include specific reference to this report. Suggested citation: NORM/NORM-VET 2017. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø / Oslo 2018. ISSN:1502-2307 (print) / 1890-9965 (electronic). This report is available at www.vetinst.no and www.antibiotikaresistens.no 1 CONTRIBUTORS AND PARTICIPANTS NORM / NORM-VET 2017 CONTRIBUTORS AND PARTICIPANTS Editors: Gunnar Skov Simonsen NORM, Univ. Hosp. North Norway Hege Salvesen Blix Norw. Inst. of Pub. Health Kari Grave Norwegian Veterinary Institute Anne Margrete Urdahl NORM-VET, Norwegian Veterinary Institute Authors: Per Espen Akselsen Antibiotic usage in humans [email protected] KAS, Haukeland Univ. Hosp. Cecilie Torp Andersen Candida spp. [email protected] Oslo Univ. Hosp. Hege Salvesen Blix Antibiotic usage in humans [email protected] Norw. Inst. of Pub. Health Dominique Caugant Meningococci [email protected] Norw. Inst. of Pub. Health Petter Elstrøm MRSA in humans [email protected] Norw. Inst. of Pub. Health Hege Enger MRSA in humans [email protected] St. Olav Univ. Hosp. Frode Width Gran MRSA in humans [email protected] St. Olav Univ. Hosp. Kari Grave Antibiotic usage in animals [email protected] Norw. Vet. Inst. Kari Olli Helgesen Antibiotic usage in animals [email protected] Norw. Vet. Inst Petter Hopp Antibiotic usage in animals [email protected] Norw. Vet. Inst. Gro Johannessen Bacteria from food [email protected] Norw. Vet. Inst. Aleksandra Jakovljev Group B streptococci [email protected] St. Olav Univ. Hosp. Morten Lindbæk Antibiotic usage in humans [email protected] ASP, Univ. of Oslo Cecilie Marie Mejdell Bacteria from animals [email protected] Norw. Vet. Inst. Mohammed Umaer Naseer Enteropathogenic bacteria in humans [email protected] Norw. Inst. of Pub. Health Marion Neteland Antibiotic usage in humans [email protected] KAS, Haukeland Univ. Hosp. Madelaine Norström Bacteria from animals and food [email protected] Norw. Vet. Inst. Karin Rønning Tuberculosis [email protected] Norw. Inst. of Pub. Health Gunnar Skov Simonsen Bacteria from humans [email protected] NORM, Univ. Hosp. North Norw. Jannice Schau Slettemeås Bacteria from animals and food [email protected] Norw. Vet. Inst. Dagfinn Skaare Haemophilus influenzae [email protected] Vestfold Hospital, Tønsberg Martin Steinbakk Bacteria from humans [email protected] Norw. Inst. of Pub. Health Anne Margrete Urdahl Bacteria from animals and food [email protected] NORM-VET, Norw. Vet. Inst. Didrik Vestrheim Pneumococci [email protected] Norw. Inst. of Pub. Health Institutions participating in NORM-VET: Norwegian Food Safety Authority Kjersti Nilsen Barkbu / Kjell Hauge / Solfrid Åmdal Norwegian Veterinary Institute Aina Steihaug Barstad / Agathe Vikre Danielsen / Gro Johannessen / Marit Gaastra Maaland / Cecilie Marie Mejdell / Madelaine Norström / Jannice Schau Slettemeås / Anne Margrete Urdahl Institutions participating in NORM: Akershus University Hospital, Lørenskog, Department of Microbiology Bjørn Odd Johnsen / Stine Martinsen Fürst Medisinsk Laboratorium, Oslo Trond Egil Ranheim / Nina Beate Johansen Førde Hospital, Department of Microbiology Reidar Hjetland / Astrid Vedde Haugesund Hospital, Department of Microbiology Liv Jorunn Sønsteby / Pirrko-Liisa Kellokumpu Haukeland Univ. Hospital, Bergen, Dep. of Microbiology Paul Christoffer Lindemann / Torunn Sneide Haukeland Innlandet Hospital, Lillehammer, Department of Microbiology Rolf Arne Sandnes / Kari Ødegaard Levanger Hospital, Department of Microbiology Angela Kümmel / Berit Harbak Molde Hospital, Department of Microbiology Einar Nilsen / Carola Christin Breivik Norstedt Norwegian Institute of Public Health, Ref. Lab. for Enteropathogenic Bacteria Mohammed Umaer Naseer / Ina Haagensen Norwegian Institute of Public Health, Ref. Lab. for H. influenzae Martin Steinbakk / Gunnhild Rødal Norwegian Institute of Public Health, Ref. Lab. for M. tuberculosis Anne Torunn Mengshoel / Annika Reichman Norwegian Institute of Public Health, Ref. Lab. for N. gonorrhoeae Martin Steinbakk / Gina Ilaug Guldahl Norwegian Institute of Public Health, Ref. Lab. for N. meningitidis Dominique Caugant / Lene Haakensen Norwegian Institute of Public Health, Ref. Lab. for S. pneumoniae Didrik Vestrheim / Anne Ramstad Alme Norwegian Institute of Public Health, Ref. Lab. for S. pyogenes Martin Steinbakk / Anne Ramstad Alme Nordland Hospital, Bodø, Department of Microbiology Sandra Åsheim / Hege Elisabeth Larsen Oslo University Hospital, Radiumhospitalet, Laboratory of Microbiology Gorm Hansen / Sunniva Fagerås Røst Oslo University Hospital, Rikshospitalet, Institute of Medical Microbiology Jørgen Vilderhøj Bjørnholt / Marcela Zamudio Oslo University Hospital, Rikshospitalet, Ref. Lab. for Mycology Cecilie Torp Andersen / Lonny Margrethe Kløvfjell Oslo University Hospital, Ullevål, Department of Microbiology Gaute Syversen / Thea Bergheim Stavanger University Hospital, Department of Microbiology Monica Regine Romstad / Anita Løvås Brekken St. Olav University Hospital, Trondheim, Department of Microbiology Hege Enger / Alexander Husby Richardsen St. Olav University Hospital, Trondheim, Ref. Lab. for MRSA Hege Enger / Frode Width Gran St. Olav University Hospital, Trondheim, Ref. Lab. for S. agalactiae Aleksandra Jakovljev / Randi Valsø Lyng Sørlandet Hospital, Kristiansand, Department of Microbiology Ståle Tofteland / Lise Hulløen-Orø Unilabs Telelab A/S, Skien Krisztina Papp / Anne Ragnhild Oseid University Hospital of North Norway, Tromsø, Department of Microbiology Gunnar Skov Simonsen / Brian Guennigsman University Hospital of North Norway, Nat. Adv. Unit on Detection of AMR Ørjan Samuelsen / Bjørg C. Haldorsen Vestfold Hospital, Tønsberg, Department of Microbiology Øystein Sverdrup / Astrid Lia Vestre Viken - Bærum Hospital, Department of Medical Microbiology Annette Onken / Inger Marie Brend Johansen Vestre Viken - Drammen Hospital, Department of Medical Microbiology Einar Tollaksen Weme / Hanne Fanuelsen Østfold Hospital, Fredrikstad, Department of Microbiology Sara Debes / Anne Cathrine Hollekim Ålesund Hospital, Department of Microbiology Einar Nilsen / Luisa Johansen NORM reference group in 2017: Martin Steinbakk Norw. Inst. Pub. Health Dag Harald Skutlaberg Haukeland Univ. Hosp. Heidi Cecilie Villmones Vestfold Hosp. Trust Aasmund Fostervold Norw. Soc. Med. Microbiol. Thea Bergheim Norw. Soc. Engineers and Technologists Jon Birger Haug Norw. Soc. Inf. Dis. Linda Rui Norw. Coll. Gen. Pract. 2 NORM / NORM-VET 2017 CONTENTS CONTENTS Introduction ……………………………………………………………………………………….............. 5 Sammendrag ..........……………………………………………………………………………….............. 7 Summary …………………………………………………………………………………………............ 10 Population statistics …………………………………………………………………………………...... 13 Usage of antimicrobial agents Usage in animals Usage of veterinary antibacterial agents ……………….……………………………………… 15 Antimicrobial and coccidiostat feed additives ……………………………………….…….. 23 National Strategy against Antibiotic Resistance (2015 – 2020) ………………………………. 23 Usage in humans Overall antibiotic sales ……………………………………………………………………….. 27 Antibiotic usage in primary care ……………………………………………………………… 32 Antibiotic usage in hospital care ……………………………………………………………. 36 National Action Plan against Antibiotic Resistance in Healthcare .………………………….. 40 Antimycotic usage in Norway ……………………………………………………………….. 43 Occurrence of antimicrobial resistance Indicator bacteria from animals Production animals ……………………………………………………………………………. 45 Sports and family animals …………................................................…..................................... 53 Indicator bacteria from food Meat ………………………………………………………………………..……………..….... 55 Vegetables ……………………………………………………………………………………. 56 Zoonotic and non-zoonotic enteropathogenic bacteria Salmonella spp. ……………………….........................………………..................................... 59 Campylobacter spp. …………………………………. .............................................................. 67 Yersinia enterocolitica .. ……….........................……………………....................................... 70 Shigella spp. .………………….............……….........................…….................................. 72 Human clinical isolates Distribution of bacterial species in blood cultures .................................................................... 75 Escherichia coli in blood cultures and urine ………….............................................................. 77 Klebsiella spp. in blood cultures and urine .…………………......................................... ......... 83 Proteus spp. in blood cultures and urine ….…………………………………………………… 89 Haemophilus influenzae in blood cultures, cerebrospinal fluids and the respiratory tract …… 94 Neisseria meningitidis in blood cultures and cerebrospinal fluids …………………………… 97 Neisseria gonorrhoeae ……………………………………………………………………….. 98 Staphylococcus aureus in blood cultures and wound specimens................................................ 99 Methicillin resistant Staphylococcus aureus (MRSA) infections in Norway 2017 …………… 102 Enterococcus
Load more

Recommended publications
  • Norwegian Journal of Epidemiology Årgang 27, Supplement 1, Oktober 2017 Utgitt Av Norsk Forening for Epidemiologi
    1 Norsk Epidemiologi Norwegian Journal of Epidemiology Årgang 27, supplement 1, oktober 2017 Utgitt av Norsk forening for epidemiologi Redaktør: Trond Peder Flaten EN NORSKE Institutt for kjemi, D 24. Norges teknisk-naturvitenskapelige universitet, 7491 Trondheim EPIDEMIOLOGIKONFERANSEN e-post: [email protected] For å bli medlem av Norsk forening for TROMSØ, epidemiologi (NOFE) eller abonnere, send e-post til NOFE: [email protected]. 7.-8. NOVEMBER 2017 Internettadresse for NOFE: http://www.nofe.no e-post: [email protected] WELCOME TO TROMSØ 2 ISSN 0803-4206 PROGRAM OVERVIEW 3 Opplag: 185 PROGRAM FOR PARALLEL SESSIONS 5 Trykk: NTNU Grafisk senter Layout og typografi: Redaktøren ABSTRACTS 9 Tidsskriftet er åpent tilgjengelig online: LIST OF PARTICIPANTS 86 www.www.ntnu.no/ojs/index.php/norepid Også via Directory of Open Access Journals (www.doaj.org) Utgis vanligvis med to regulære temanummer pr. år. I tillegg kommer supplement med sammendrag fra Norsk forening for epidemiologis årlige konferanse. 2 Norsk Epidemiologi 2017; 27 (Supplement 1) The 24th Norwegian Conference on Epidemiology Tromsø, November 7-8, 2017 We would like to welcome you to Tromsø and the 24th conference of the Norwegian Epidemiological Association (NOFE). The NOFE conference is an important meeting point for epidemiologists to exchange high quality research methods and findings, and together advance the broad research field of epidemiology. As in previous years, there are a diversity of topics; epidemiological methods, cardiovascular disease, diabetes, cancer, nutrition, female health, musculo-skeletal diseases, infection and behavioral epidemiology, all within the framework of this years’ conference theme; New frontiers in epidemiology. The conference theme reflects the mandate to pursue methodological and scientific progress and to be in the forefront of the epidemiological research field.
    [Show full text]
  • Conjugate and Prodrug Strategies As Targeted Delivery Vectors for Antibiotics † † ‡ Ana V
    Review Cite This: ACS Infect. Dis. XXXX, XXX, XXX−XXX pubs.acs.org/journal/aidcbc Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics † † ‡ Ana V. Cheng and William M. Wuest*, , † Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia 30322, United States ‡ Emory Antibiotic Resistance Center, Emory School of Medicine, 201 Dowman Drive, Atlanta, Georgia 30322, United States ABSTRACT: Innate and developed resistance mechanisms of bacteria to antibiotics are obstacles in the design of novel drugs. However, antibacterial prodrugs and conjugates have shown promise in circumventing resistance and tolerance mechanisms via directed delivery of antibiotics to the site of infection or to specific species or strains of bacteria. The selective targeting and increased permeability and accumu- lation of these prodrugs not only improves efficacy over unmodified drugs but also reduces off-target effects, toxicity, and development of resistance. Herein, we discuss some of these methods, including sideromycins, antibody-directed prodrugs, cell penetrating peptide conjugates, and codrugs. KEYWORDS: oligopeptide, sideromycin, antibody−antibiotic conjugate, cell penetrating peptide, dendrimer, transferrin inding new and innovative methods to treat bacterial F infections comes with many inherent challenges in addition to those presented by the evolution of resistance mechanisms. The ideal antibiotic is nontoxic to host cells, permeates bacterial cells easily, and accumulates at the site of infection at high concentrations. Narrow spectrum drugs are also advantageous, as they can limit resistance development and leave the host commensal microbiome undisturbed.1 However, various resistance mechanisms make pathogenic infections difficult to eradicate: Many bacteria respond to antibiotic pressure by decreasing expression of active transporters and porins2 and 3,4 Downloaded via EMORY UNIV on April 18, 2019 at 12:34:17 (UTC).
    [Show full text]
  • [Cu2(Mand)2(Hmt)]–MOF: a Synergetic Effect Between Cu(II)
    Article 3 1 [Cu2(mand)2(hmt)]–MOF: A Synergetic Effect between Cu(II) and Hexamethylenetetramine in the Henry Reaction 1 1 1 2 2, Horat, iu Szalad , Natalia Candu , Bogdan Cojocaru , Traian D. Păsătoiu , Marius Andruh * and Vasile I. Pârvulescu 1,* 1 Department of Organic Chemistry, Biochemistry and Catalysis, Catalysis and Catalytic Processes Research Centre, Faculty of Chemistry, University of Bucharest, Bd. Regina Elisabeta nr. 4-12, 020462 Bucharest, Romania; [email protected] (H.S.); [email protected] (N.C.); [email protected] (B.C.) 2 Faculty of Chemistry, University of Bucharest, Department of Inorganic Chemistry, 23 Dumbrava Ro¸sie Street, sector 2, 020462 Bucharest, Romania; [email protected] * Correspondence: [email protected] (M.A.); [email protected] (V.I.P.) Received: 9 January 2020; Accepted: 12 February 2020; Published: 13 February 2020 3 Abstract: [Cu2(mand)2(hmt)] H2O (where mand is totally deprotonated mandelic acid (racemic 1 · mixture) and hmt is hexamethylenetetramine) proved to be a stable metal–organic framework (MOF) structure under thermal activation and catalytic conditions, as confirmed by both the in situ PXRD (Powder X-ray diffraction) and ATR–FTIR (Attenuated total reflection-Fourier-transform infrared spectroscopy) haracterization. The non-activated MOF was completely inert as catalyst for the Henry reaction, as the accessibility of the substrates to the channels was completely blocked by H-bonded water to the mand entities and CO2 adsorbed on the Lewis basic sites of the hmt. Heating at 140 ◦C removed these molecules. Only an insignificant change in the relative ratios of the XRD facets due to the capillary forces associated to the removal of the guest molecules from the network has been observed.
    [Show full text]
  • Evaluation of Remdesivir and Hydroxychloroquine on Viral Clearance in Covid-19 Patients: Results from the NOR-Solidarity Randomised Trial
    Evaluation of remdesivir and hydroxychloroquine on viral clearance in Covid-19 patients: Results from the NOR-Solidarity Randomised Trial Andreas Barratt-Due1,2,9,*, Inge Christoffer Olsen3, Katerina Nezvalova Henriksen4,5, Trine Kåsine1,9, Fridtjof Lund-Johansen2,6, Hedda Hoel7,9,10, Aleksander Rygh Holten8,9, Anders Tveita11, Alexander Mathiessen12, Mette Haugli13, Ragnhild Eiken14, Anders Benjamin Kildal15, Åse Berg16, Asgeir Johannessen9,17, Lars Heggelund18,19, Tuva Børresdatter Dahl1,10, Karoline Hansen Skåra10, Pawel Mielnik20, Lan Ai Kieu Le21, Lars Thoresen22, Gernot Ernst23, Dag Arne Lihaug Hoff24, Hilde Skudal25, Bård Reiakvam Kittang26, Roy Bjørkholt Olsen27, Birgitte Tholin28, Carl Magnus Ystrøm29, Nina Vibeche Skei30, Trung Tran2, Susanne Dudman9,39, Jan Terje Andersen9,31, Raisa Hannula32, Olav Dalgard9,33, Ane-Kristine Finbråten7,34, Kristian Tonby9,35, Bjorn Blomberg36,37, Saad Aballi38, Cathrine Fladeby39, Anne Steffensen9, Fredrik Müller9,39, Anne Ma Dyrhol-Riise9,35, Marius Trøseid9,40 and Pål Aukrust9,10,40 on behalf of the NOR-Solidarity study group# 1Division of Critical Care and Emergencies, Oslo University Hospital, 0424 Oslo, Norway 2Division of laboratory Medicine, Dept. of Immunology, Oslo University Hospital, 0424 Oslo, Norway 3Department of Research Support for Clinical Trials, Oslo University Hospital, 0424 Oslo, Norway 4Department of Haematology, Oslo University Hospital, 0424 Oslo, Norway 5Hospital Pharmacies, South-Eastern Norway Enterprise, 0050 Oslo, Norway 6ImmunoLingo Covergence Centre, University
    [Show full text]
  • 0996 Date: February 2009 Revision: June 2016 DOT Number: UN 1328
    Right to Know Hazardous Substance Fact Sheet Common Name: HEXAMINE Synonyms: Hexamethylenetetramine; Methenamine CAS Number: 100-97-0 Chemical Name: 1,3,5,7-Tetraazatricyclo[3.3.1.13,7]Decane RTK Substance Number: 0996 Date: February 2009 Revision: June 2016 DOT Number: UN 1328 Description and Use EMERGENCY RESPONDERS >>>> SEE LAST PAGE Hexamine is a colorless to white, odorless, crystalline (sand- Hazard Summary like) powder. It is used in adhesives, coatings, and sealing Hazard Rating NJDHSS NFPA compounds, and as a medication. HEALTH 2 - FLAMMABILITY 1 - REACTIVITY 0 - COMBUSTIBLE POISONOUS GASES ARE PRODUCED IN FIRE Reasons for Citation Hazard Rating Key: 0=minimal; 1=slight; 2=moderate; 3=serious; Hexamine is on the Right to Know Hazardous Substance 4=severe List because it is cited by DOT. Hexamine can affect you when inhaled. Contact can irritate the skin and eyes. Inhaling Hexamine can irritate the nose, throat and lungs. Hexamine can cause nausea, vomiting, diarrhea and abdominal pain. Hexamine may cause a skin allergy and an asthma-like allergy. SEE GLOSSARY ON PAGE 5. Finely dispersed Hexamine particulate or powdered dust is an explosion hazard. FIRST AID Eye Contact Immediately flush with large amounts of water for at least 15 minutes, lifting upper and lower lids. Remove contact Workplace Exposure Limits lenses, if worn, while rinsing. No occupational exposure limits have been established for Skin Contact Hexamine. However, it may pose a health risk. Always follow Quickly remove contaminated clothing. Immediately wash safe work practices. contaminated skin with large amounts of water. Inhalation Remove the person from exposure. Begin rescue breathing (using universal precautions) if breathing has stopped and CPR if heart action has stopped.
    [Show full text]
  • Swedres-Svarm 2019
    2019 SWEDRES|SVARM Sales of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2019 A report on Swedish Antibiotic Sales and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Olov Aspevall and Vendela Wiener, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden Solna. SE-171 82 Solna, Sweden Östersund. Box 505, SE-831 26 Östersund, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text, tables and figures may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2019. Sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 19088 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2019 as a pdf in publicerat-material/ or at www.sva.se/swedres-svarm/ your mobile device, for reading and sharing. Use the camera in you’re mobile device or download a free Layout: Dsign Grafisk Form, Helen Eriksson AB QR code reader such as i-nigma in the App Store for Apple Print: Taberg Media Group, Taberg 2020 devices or in Google Play.
    [Show full text]
  • New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics
    pharmaceuticals Review New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics Nicola Principi 1, Alberto Argentiero 2, Cosimo Neglia 2, Andrea Gramegna 3,4 and Susanna Esposito 2,* 1 Università degli Studi di Milano, 20122 Milan, Italy; [email protected] 2 Pediatric Clinic, Pietro Barilla Children’s Hospital, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy; [email protected] (A.A.); [email protected] (C.N.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, 20122 Milan, Italy; [email protected] 4 Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-052-190-3524 Received: 29 September 2020; Accepted: 19 October 2020; Published: 23 October 2020 Abstract: Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles. Despite differences in the localization and severity, all these diseases are due mainly to Gram-positive bacteria, especially Staphylococcus aureus and Streptococcus pyogenes. aSSTI incidence increased considerably in the early years of this century due to the emergence and diffusion of community-acquired methicillin-resistant S. aureus (CA-MRSA). Despite the availability of antibiotics effective against CA-MRSA, problems of resistance to these drugs and risks of significant adverse events have emerged. In this paper, the present knowledge on the potential role new antibiotics for the treatment of pediatric aSSTIs is discussed. The most recent molecules that have been licensed for the treatment of aSSTIs include ozenoxacin (OZ), ceftaroline fosamil (CF), dalbavancin (DA), oritavancin (OR), tedizolid (TD), delafloxacin (DL), and omadacycline (OM).
    [Show full text]
  • United States Patent Office Patented Oct
    3,004,026 United States Patent Office Patented Oct. 10, 1961 1. 3,004,026 septic. Thus, it has been recommended that a salt ex-. HEXAMETHYLENETETRAMINE HIPPURATE hibiting an acid reaction, such as ammonium chloride, Alexander Galat, 126 Buckingham Road, Yonkers, NY. ammonium nitrate, sodium acid phosphate or the like, No Drawing. Filed Aug. 28, 1959, Ser. No. 836,618 be administered together with Methenamine. However, 1. Claim. C. 260-248.5) 5 impractically and/or dangerously high dosages of such salts must be given in order to make the urine acidic and This invention relates to a new and useful organic com even so acidification of the urine does not occur with all pound. More particularly, this invention relates to a new patients. - . organic compound useful as a urinary tract antiseptic. In Another approach that has been employed in an at an even more specific aspect thereof, this invention relates O tempt to solve the difficulty involves administering to hexamethylenetetramine hippurate. Methenamine in the form of a salt with an organic acid. The principal object of this invention is to provide It is postulated that decomposition of such a salt in the hexamethylenetetramine hippurate, a new organic com urine will result in the production of the acid medium re pound of high utility. quired for manifestation of the antiseptic action of Corollary objects of this invention will become appar 15 Methenamine. ent as the description thereof proceeds. Salts of Methenamine with such acids as anhydro For the better understanding of this invention, the methylenecitric, acetylsalicylic, borocitric, citrosulfuric, following example is a complete description of a pre mandelic, phenoxyacetic, salicyclic, sulfosalicylic, salicyl ferred procedure for the preparation of the new and use oxyacetic, sulfoxylic, and the like have been prepared ful compound of this invention.
    [Show full text]
  • Improving Ambulance Coverage in a Mixed
    Delft University of Technology Improving ambulance coverage in a mixed urban-rural region in Norway using mathematical modeling van den Berg, Pieter L.; Fiskerstrand, Peter; Aardal, Karen; Einerkjær, Jørgen; Thoresen, Trond; Røislien, Jo DOI 10.1371/journal.pone.0215385 Publication date 2019 Document Version Final published version Published in PLoS ONE Citation (APA) van den Berg, P. L., Fiskerstrand, P., Aardal, K., Einerkjær, J., Thoresen, T., & Røislien, J. (2019). Improving ambulance coverage in a mixed urban-rural region in Norway using mathematical modeling. PLoS ONE, 14(4), 1-14. [e0215385]. https://doi.org/10.1371/journal.pone.0215385 Important note To cite this publication, please use the final published version (if applicable). Please check the document version above. Copyright Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons. Takedown policy Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim. This work is downloaded from Delft University of Technology. For technical reasons the number of authors shown on this cover page is limited to a maximum of 10. RESEARCH ARTICLE Improving ambulance coverage in a mixed urban-rural region in Norway using mathematical modeling 1 2 3,4 2 Pieter L. van den BergID *, Peter Fiskerstrand
    [Show full text]
  • Sivextro (Tedizolid Phosphate)
    ___________________ ______________ HIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS These highlights do not include all the information needed to TM None (4) use SIVEXTRO safely and effectively. See full prescribing _______________ __________ information for SIVEXTRO. WARNINGS AND PRECAUTIONS • Patients with neutropenia: The safety and efficacy of SIVEXTRO (tedizolid phosphate) for injection, for SIVEXTRO in patients with neutropenia (neutrophil counts intravenous use <1000 cells/mm3) have not been adequately evaluated. In an SIVEXTRO (tedizolid phosphate) tablet, for oral use animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes. Initial U.S. Approval: 2014 Consider alternative therapies in neutropenic patients. (5.1) _________________ _________________ • Clostridium difficile-associated diarrhea: Evaluate if diarrhea INDICATIONS AND USAGE occurs. (5.2) SIVEXTRO is an oxazolidinone-class antibacterial drug indicated ___________________ ADVERSE REACTIONS ______________ in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (1) The most common adverse reactions (>2%) are nausea, headache, diarrhea, vomiting, and dizziness. (6) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that To report SUSPECTED ADVERSE REACTIONS, contact are proven or strongly suspected to be caused by bacteria. Cubist Pharmaceuticals at 1-877-282-4786 or FDA at 1-800­ ______________ DOSAGE AND ADMINISTRATION ______________ FDA -1088 or www.fda.gov/medwatch. 200 mg administered once daily orally or as an intravenous (IV) ________________________________________________________ infusion over 1 hour for six (6) days. (2.1) ______________DOSAGE FORMS AND STRENGTHS _____________ See 17 for PATIENT COUNSELING INFORMATION.
    [Show full text]
  • Tedizolid Phosphate (SIVEXTRO) Monograph
    Tedizolid phosphate (SIVEXTRO) Monograph Tedizolid (Sivextro) National Drug Monograph March 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Tedizolid phosphate is an oxazolidinone antibiotic prodrug, which inhibits Action bacterial protein synthesis in its active form by binding to the 50S subunit of the bacterial ribosome. It has shown in vitro activity against Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus), and Enterococcus faecalis.1 Indications under Review in Tedizolid phosphate is indicated for the treatment of acute bacterial skin and this document (may include skin structure infections (ABSSSI) caused by select Gram-positive susceptible off label) isolates. Dosage Form(s) Under Intravenous Powder for Solution, 200mg Review Oral Tablet, 200mg REMS REMS No REMS Pregnancy Rating Category C Executive Summary Efficacy The FDA approval of tedizolid phosphate was based on two multinational phase 3 non-inferiority trials evaluating tedizolid phosphate 200mg once daily for 6 days vs linezolid 600mg twice daily for 10 days for the treatment of ABSSSI.2,3 The primary efficacy endpoint for these pivotal trials was early clinical response at 48 – 72 hours. The definition of early clinical response was no increase in lesion surface area from baseline and oral temperature of ≤ 37.6°C in one trial and ≥20% reduction in lesion surface area compared to baseline in the other.
    [Show full text]
  • F1y3x CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1
    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
    [Show full text]